Dataset Information


Gut Microbiota Modulation and Fecal Transplantation: An Overview on Innovative Strategies for Hepatic Encephalopathy Treatment.

ABSTRACT: Hepatic encephalopathy (HE) is a major complication of cirrhosis, which is associated with gut microbial composition and functional alterations. Current treatments largely focus on gut microbiota using lactulose, rifaximin and other agents. However, despite these treatments, patients with HE have a high rate of readmission, morbidity and cognitive impairment. Fecal microbiota transplant (FMT) involves introduction of a donor microbiota into a recipient and is currently mainly used for recurrent C. difficile infection (rCDI). The role of FMT in cirrhosis and HE is evolving. There have been two randomized clinical trials (RCT) and several case reports/series in cirrhosis. Both RCTs were safety-focused phase 1 trials. One involved pre-FMT antibiotics and FMT enema versus standard of care, while the other involved 15 FMT capsules versus placebo without pre-FMT antibiotics. There was evidence of safety in both trials and the FMT group demonstrated reduction in hospitalizations compared to the non-FMT group. Changes in microbial function centered around short-chain fatty acids, bile acids and brain function showed improvement in the FMT groups. Long-term follow-up demonstrated continued safety and reduction in the antibiotic-resistance gene carriage. However, larger trials of FMT in HE are needed that can refine the dose, duration and route of FMT administration.

PROVIDER: S-EPMC7830387 | BioStudies |

REPOSITORIES: biostudies

Similar Datasets

2021-01-01 | S-EPMC7850310 | BioStudies
2018-01-01 | S-EPMC6224514 | BioStudies
2019-01-01 | S-EPMC6881239 | BioStudies
| S-EPMC6858162 | BioStudies
2018-01-01 | S-EPMC6214502 | BioStudies
2020-01-01 | S-EPMC6989129 | BioStudies
2013-01-01 | S-EPMC3615021 | BioStudies
| S-EPMC7509309 | BioStudies
2019-01-01 | S-EPMC6398649 | BioStudies
2020-01-01 | S-EPMC7171286 | BioStudies